SYDNEY, Jan. 30, 2014 /PRNewswire/ -- Novogen
Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development
company, today announced it will host a corporate update with
Graham Kelly, Ph.D., Novogen Group
Executive Chairman and Chief Executive Officer, and David Brown, Ph.D., Chief Scientific Officer on
Friday, February 7, 2014 at
8:00 a.m. (Sydney local time). This corresponds to
Thursday, February 6, 2014 at
4:00 p.m. U.S. Eastern Standard
Time.
(Logo:
http://photos.prnewswire.com/prnh/20131220/NY36990LOGO)
A live audio webcast with slides will be available on the
company's website, www.novogen.com as part of the webcast.To
participate in the live teleconference, please dial the following
numbers fifteen minutes before the call is scheduled to begin: U.S.
and Canada, 877-303-5846;
Australia, 1800005989 (toll-free)
or 02-8223-9773 (toll). Callers in other countries should dial
315-625-3081 (toll charges apply). The archived webcast will be
available for two weeks on the company's website, or until
February 21, 2014.
About Novogen Limited
Novogen is an public, Australian biotechnology company whose
shares trade on both the Australian Securities Exchange ('NRT') and
NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in
New Haven, Connecticut. The
Company has two main drug technology platforms known as
super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs
target cancer stem cells and are being developed for the treatment
of ovarian cancer and glioblastoma. ATM drugs target the cancer
cell cytoskeleton and are being developed for the treatment of
melanoma, prostate cancer and neuroblastoma. Novogen has entered
into a joint venture with Yale
University known as CanTx Inc. with the aim of developing
personalized chemotherapy for patients with ovarian cancer.
Further information is available on the Company's website,
www.novogen.com.
For Further Information Contact:
David Carey/Tanner
Kaufman
Lazar Partners Ltd.
212 867 1762
dcarey@lazarpartners.com
tkaufman@lazarpartners.com
SOURCE Novogen Limited